DARBITOP 60MG

Darbitop 60Mcg/0.3Ml Inj is classified as a ‘blood-forming agent’ and is primarily utilized to treat anaemia (a low red blood cell count) in individuals with long-term serious (chronic) kidney disease and those undergoing chemotherapy for certain types of cancer (excluding cancers of the bone marrow or blood cells). This medication aids in reversing anaemia and decreasing the necessity for blood transfusions. Anaemia arises when the body has a reduced quantity of red blood cells or haemoglobin. In cases of chronic kidney disease, the kidneys become damaged and fail to filter the blood effectively, resulting in anaemia.

Darbitop 60Mcg/0.3Ml Inj contains the protein ‘Darbepoetin alfa’, which signals the bone marrow to increase the production of red blood cells. It acts as a biologic response modifier and an erythropoiesis-stimulating protein. In chronic kidney disease, when the kidneys do not produce enough ‘erythropoietin protein’ that is essential for red blood cell formation, Darbitop 60Mcg/0.3Ml Inj stimulates the bone marrow to produce this protein.

The injection of Darbitop 60Mcg/0.3Ml Inj will be administered by a healthcare professional. Self-administration is not advised. Common side effects associated with Darbitop 60Mcg/0.3Ml Inj include shortness of breath, cough, low blood pressure during dialysis, headache, body aches, diarrhea, pain at the injection site, and abdominal discomfort. Most of these side effects do not necessitate medical intervention and typically resolve on their own over time. However, if side effects persist, it is important to contact your doctor.

If you have uncontrolled or untreated high blood pressure or red cell aplasia (a form of anaemia) caused by darbepoetin alfa or epoetin alfa, please inform your doctor prior to using Darbitop 60Mcg/0.3Ml Inj to prevent any complications. Additionally, disclose all other medications you are currently taking, as they may influence the effectiveness of Darbitop 60Mcg/0.3Ml Inj. Seek immediate medical attention if you experience weakness, lightheadedness, fatigue, shortness of breath, or if your skin appears pale, as these may indicate that the body has stopped producing red blood cells.